Noema Pharma, a Basel, Switzerland-based clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, raised USD 112M in Series B funding.
The round was led by Forbion and Jeito Capital with participation from UPMC Enterprises, Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus. In conjunction with the funding, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the Board of Directors of Noema Pharma.
The company intends to use the funds for continued development of its diversified pipeline focused on central nervous system disorders.
Founded in 2019 and led by CEO Luigi Costa, Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The company has a differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. It has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort.
The Series B financing follows a CHF 54M (approx. USD 60M) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
FinSMEs
07/03/2023